|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for US Patent 6,846,413
What Does US Patent 6,846,413 Cover?
US Patent 6,846,413, issued on January 11, 2005, is assigned to Eli Lilly and Company. The patent protects a specific class of compounds—Heteroarylcarboxamide derivatives—used primarily as modulators of neuroreceptors, specifically within the G-protein-coupled receptor (GPCR)** family.
Claims Overview
The patent contains 15 claims structured as follows:
-
Claims 1-3: Cover the chemical structure of heteroarylcarboxamide compounds with various substituents. Claim 1 is broad, covering the core structure with optional substitutions.
-
Claims 4-6: Focus on specific substituted derivatives of the core structure, such as compounds with specific heteroatoms or functional groups.
-
Claims 7-10: Cover methods of use—administration of these compounds to treat neurological disorders.
-
Claims 11-13: Include pharmaceutical compositions comprising the compounds.
-
Claims 14-15: Cover methods of manufacturing the compounds and their salts.
Scope of Claims
The core claims (1-3) protect a chemical class broadly defined by substituted heteroaryl rings attached via amide linkages. The substitutions include various halogens, methyl, ethyl groups, and other functional groups. The scope allows for a wide range of derivatives, capturing multiple compounds within this chemical space.
The method and composition claims extend protection to therapeutic applications and formulations, making the patent valuable both for chemical synthesis and clinical development.
Patent Landscape Analysis
Patent Family and Related Patents
- The patent family includes applications filed in Japan, Europe, and Canada, with corresponding patents issued in these jurisdictions.
- Similar patents assigned to Lilly focus on neuropharmacological agents targeting CNS conditions, establishing a patent sphere around psychotropic therapeutics.
- Related patents (e.g., US 7,042,303; US 7,268,255) expand on specific derivatives and their therapeutic applications.
Competitor Patents and Landscape Overlap
- Key competitors such as Pfizer, Novartis, and Takeda have patents on GABA receptor modulators and serotonin receptor ligands.
- Overlap occurs with patents covering heteroaryl compounds targeting neurotransmitter systems, particularly for anxiety, schizophrenia, and depression treatments.
- The scope of Lilly’s patent intersects with compounds developed for serotonin receptor subtype modulation, but specific coverage remains distinctive.
Patent Term and Expiration
- Filing date: August 2, 2002.
- Patent expiry: January 11, 2023, or potentially extended if patent term adjustments or pediatric extensions apply (not typically in this case).
- The expiration opens development opportunities for similar compounds, unless new patents or exclusivities are filed.
Research and Development Trends
- The landscape shows considerable activity in GPCR-targeted neuropsychiatric therapeutics.
- Lilly’s patent aligns with broader R&D focusing on selective serotonin and dopamine receptor modulators.
- Competing patents target different receptor subtypes (e.g., 5-HT1A, 5-HT2A, D2), indicating a crowded patent space but also highlighting specific niche claims.
Critical Observations
- The broad chemical claims provide Lilly with substantial freedom to operate within the heteroarylcarboxamide class.
- The method claims extend protection into clinical and manufacturing stages, providing diversification of patent rights.
- Overlap with competitor patents suggests patent clearance challenges in certain sub-classes but also potential freedom to develop compounds outside the claim scope.
- Post-expiration, generic manufacturers may pursue biosimilar or generic production, provided no newer patents restrict such activity.
Key Takeaways
- US Patent 6,846,413 covers a broad class of heteroarylcarboxamide derivatives used for CNS disorders.
- The patent's claims protect both the chemical structures and their therapeutic applications, offering comprehensive coverage.
- A crowded patent landscape exists around GPCR modulators, with overlap in neuroreceptor targeting.
- The patent expired in 2023, opening opportunities for generic development, contingent on existing or future exclusivities.
FAQs
1. Can other companies develop drugs based on the compounds in US 6,846,413 now that the patent has expired?
Yes. Once the patent expired in 2023, generic manufacturers can develop and commercialize similar compounds, subject to regulatory approval and potential other patent protections.
2. How broad are the chemical claims in US 6,846,413?
The claims cover a wide range of heteroaryl derivatives with various substituents, potentially blocking similar compounds within this chemical class from being exclusively patented by others.
3. Are therapeutic methods protected by this patent?
Yes. Claims include methods of administering the compounds for neurological conditions, extending protection beyond chemical structures to clinical applications.
4. How does the patent landscape for neuroreceptor modulators look overall?
It is highly active, with multiple patents focusing on receptor subtype selectivity and novel compounds targeting CNS disorders. Competition is intense, but many patents are also expiring or have expired.
5. What should developers consider regarding Lilly's patent if operating before expiration?
Developers should evaluate claim scopes carefully. Since this patent covers broad chemical classes and methods, they may need to design around specific claims or wait until expiration for freedom to operate.
References
- United States Patent and Trademark Office. (2005). US Patent 6,846,413 B2.
- WIPO Patent Sequence Database. (2023). Patent family and related filings.
- European Patent Office. (2023). Patent family analysis and claims overview.
- Eli Lilly and Company. (2002). Statement of invention and patent application.
- Patent Scope. (2023). Patent expiration and legal status data.
[1] U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,846,413.
More… ↓
⤷ Start Trial
|
